The Company is a Korea-based company mainly engaged in the research and development of anti-angiogenic immunotherapy drugs. The Company s pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The Company sells its products in domestic and overseas markets.
Headquarters
12-55, Sandan-Gil, Hwasun-Eup
Hwaseong; Gyeonggi;
Contact Details: Purchase the Vaxcell-Bio Co.,Ltd. report to view the information.
Website: http://www.vaxcell-bio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service